Infection and drug resistance · 2024
Bloodstream Infection Combined with Thoracic Infection Caused by Mycoplasma hominis: A Case Report and Review of the Literature.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Conway Rachel, Duncan Colleen, Foster Robert A, Kersh Gilbert J, Raverty Stephen, Gelatt Tom, Frank Chad
Аннотация
OBJECTIVE: Mycoplasma hominis is usually found in urogenital tract infections and is associated with several extra-genitourinary infections, including septic arthritis, bacteremia, and meningitis. Here, we report a rare case of M. hominis induced bloodstream infection with thoracic inflammation in a surgical patient.
METHODS: A 56-year-old male who underwent surgery for multiple pelvic and rib fractures developed fever, pleural effusion, and wound exudation despite receiving prophylactic anti-infection treatment with cefotiam. Then, replacing the broad-spectrum antimicrobial drugs such as biapenem, imipenem, linezolid still had no obvious curative effect. Meanwhile, a total of 4 groups of blood cultures were collected from patients, of which 2 groups reported positive results 2 to 3 days after specimen collection. At the same time, the patient's pleural effusion and wound pus were also cultured, and transparent needle-like small colonies grew on Columbia blood agar plates within 2 to 3 days after inoculation.
RESULTS: The cultured transparent pinpoint-like small colonies were identified as M. hominis by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16SrRNA sequencing. The results of antibiotic susceptibility testing (AST) showed that M. hominis was susceptible to doxycycline, minocycline, josamycin, sparfloxacin, and spectinomycin but resistant to azithromycin, clarithromycin, norfloxacin, roxithromycin, and ofloxacin. According to the AST results and clinical symptoms, moxifloxacin was selected as targeted therapy for M. hominis infection, and cefoperazone/sulbactam was combined to prevent the infection of other gram-negative bacteria. Finally, the patient was cured successfully.
CONCLUSION: Although M. hominis bloodstream and thoracic infections are rare, they cannot be ignored. M. hominis is intrinsically resistant to agents that work on bacterial cell wall synthesis used. Fluoroquinolones could be kept as potential active and thus a likely curative factor. When routine empirical anti-infection treatment is ineffective, the pathogen should be identified as early as possible. If necessary, gene sequencing technology should be used for diagnosis and sensitive anti-infection drug treatment should be promptly administered to reduce the risk of bloodstream infections.
METHODS: A 56-year-old male who underwent surgery for multiple pelvic and rib fractures developed fever, pleural effusion, and wound exudation despite receiving prophylactic anti-infection treatment with cefotiam. Then, replacing the broad-spectrum antimicrobial drugs such as biapenem, imipenem, linezolid still had no obvious curative effect. Meanwhile, a total of 4 groups of blood cultures were collected from patients, of which 2 groups reported positive results 2 to 3 days after specimen collection. At the same time, the patient's pleural effusion and wound pus were also cultured, and transparent needle-like small colonies grew on Columbia blood agar plates within 2 to 3 days after inoculation.
RESULTS: The cultured transparent pinpoint-like small colonies were identified as M. hominis by matrix-assisted laser desorption-ionization time-of-flight mass spectrometry (MALDI-TOF MS) and 16SrRNA sequencing. The results of antibiotic susceptibility testing (AST) showed that M. hominis was susceptible to doxycycline, minocycline, josamycin, sparfloxacin, and spectinomycin but resistant to azithromycin, clarithromycin, norfloxacin, roxithromycin, and ofloxacin. According to the AST results and clinical symptoms, moxifloxacin was selected as targeted therapy for M. hominis infection, and cefoperazone/sulbactam was combined to prevent the infection of other gram-negative bacteria. Finally, the patient was cured successfully.
CONCLUSION: Although M. hominis bloodstream and thoracic infections are rare, they cannot be ignored. M. hominis is intrinsically resistant to agents that work on bacterial cell wall synthesis used. Fluoroquinolones could be kept as potential active and thus a likely curative factor. When routine empirical anti-infection treatment is ineffective, the pathogen should be identified as early as possible. If necessary, gene sequencing technology should be used for diagnosis and sensitive anti-infection drug treatment should be promptly administered to reduce the risk of bloodstream infections.